RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2004; 129(15): 831-835
DOI: 10.1055/s-2004-823030
DOI: 10.1055/s-2004-823030
Übersichten
Pharmakologie / Kardiologie
© Georg Thieme Verlag Stuttgart · New York
Genpolymorphismen in Arzneimittel-abbauenden Enzymen
Bedeutung für die Therapie mit β-BlockernGenetic polymorphisms in drug metabolizing enzymesImpact on treatment with β-blockersWeitere Informationen
Publikationsverlauf
eingereicht: 9.2.2004
akzeptiert: 18.3.2004
Publikationsdatum:
31. März 2004 (online)
GlossarCYP: Cytochrom P450 EM: Extensive metabolizer (normale metabolische Aktivität) IM: Intermediate metabolizer (reduzierte metabolische Aktivität) PM: Poor metabolizer (keine metabolische Aktivität) UAW: Unerwünschte Arzneimittelwirkung UM: Ultrarapid metabolizer (gesteigerte metabolische Aktivität) |
Literatur
- 1 Abrahamsson B, Lücker P, Olofsson B. et al . The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol. 1990; 30 S46-S54
- 2 BERLIN-CHEMIE AG .Fachinformation Nebilet®;. 2003
- 3 Cheymol G, Woestenborghs R, Snoeck E. et al . Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol. 1997; 51 493-498
- 4 Clark D W, Morgan A K, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol. 1984; 18 965-967
- 5 Collette D, Thürmann P A. Unerwünschte Arzneimittelwirkungen. Erbliche Unterschiede im Arzneistoffmetabolismus. Dtsch Med Wochenschr. 2002; 127 1025-1028
- 6 Dahl M L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995; 274 516-520
- 7 Deroubaix X, Lins R L, Lens S. et al . Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers. Int J Clin Pharmacol Ther. 1996; 34 61-70
- 8 Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med. 2001; 7 285-287
- 9 Eichelbaum M, Spannbrucker N, Steincke B, Dengler H J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979; 16 183-187
- 10 Evans W E, McLeod H L. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348 538-549
- 11 Gottlieb S S, Fisher M L, Kjekshus J. et al . Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation. 2002; 105 1182-1188
- 12 Graff D W, Williamson K M, Pieper J A. et al . Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol. 2001; 41 97-106
- 13 Griese E U, Zanger U M, Brudermanns U. et al . Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998; 8 15-26
- 14 Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998; 63 1097-1108
- 15 Human Allele Nomenclature Committee .Home Page of the Human Cytochrome P450 (CYP). http://www.imm.ki.se/CYPalleles/ 2004
- 16 Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369 89-104
- 17 Keating G M, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003; 63 1697-1741
- 18 Komajda M, Follath F, Swedberg K. et al . The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003; 24 464-474
- 19 Lacourciere Y, Poirier L, Lefebvre J, Archambault F, Cleroux J. Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivolol in patients with confirmed mild to moderate hypertension. J Cardiovasc Pharmacol. 1995; 25 619-624
- 20 Lamba J K, Lin Y S, Schuetz E G, Thummel K E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54 1271-1294
- 21 Leineweber K, Büscher R, Bruck H, Brodde O E. beta-Adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369 1-22
- 22 Lemmer B. Betarezeptorenblocker. Berlin Heidelberg: Springer-Verlag In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport 2001 2001: 287-296
- 23 Lennard M S, Silas J H, Freestone S, Ramsay L E, Tucker G T, Woods H F. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med. 1982; 307 1558-1560
- 24 Lennard M S, Tucker G T, Silas J H, Woods H F. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica. 1986; 16 435-447
- 25 Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986; 8 S16-20
- 26 Lohse M J, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res. 2003; 93 896-906
- 27 Mahgoub A, Idle J R, Dring L G, Lancaster R, Smith R L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977; 2 584-586
- 28 McNeely W, Goa K L. Nebivolol in the management of essential hypertension: a review. Drugs. 1999; 57 633-651
- 29 Meyer U A. Pharmacogenetics and adverse drug reactions. Lancet. 2000; 356 1667-1671
- 30 Raimundo S, Fischer J, Eichelbaum M, Griese E U, Schwab M, Zanger U M. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 2000; 10 577-581
- 31 Rau T, Heide R, Bergmann K. et al . Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002; 12 465-472
- 32 Roden D M. Cardiovascular pharmacogenomics. Circulation. 2003; 108 3071-3074
- 33 Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997; 60 284-295
- 34 Siddoway L A, Thompson K A, McAllister C B. et al . Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987; 75 785-791
- 35 Van Rooy P, De Crée J. Haemodynamic effects of nebivolol in poor and extensive metabolisers. Drug Investig. 1991; 3 161-163
- 36 Wadworth A N, Murdoch D, Brogden R N. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991; 42 468-510
- 37 Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987; 24 213-220
- 38 Wuttke H, Rau T, Heide R. et al . Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther. 2002; 72 429-437
- 39 Zanger U M, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369 23-37
- 40 Zhou H H, Wood A J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 1995; 57 518-524
Prof. Dr. med. Thomas Eschenhagen
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
Telefon: +49/40/428033180
Fax: +49/40/428034876
eMail: t.eschenhagen@uke.uni-hamburg.de